We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

Clearing the Decks for Deep Thinking Is Vital in Science
Collaboration has fueled many achievements made by the IMF and the International Myeloma Working Group (IMWG). But scientific advances also come from the kind of “deep thinking” that there is little time for in today’s hectic world. In his blog this week, IMF Chairman Dr. Brian Durie explores why both types of settings are important to push the research needle forward. To read Dr. Durie’s blog, click HERE.

European Medicines Agency Pushes for Empliciti for the Treatment of Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) reviewed the monoclonal antibody Empliciti® (elotuzumab) as part of the European Medicine Agency’s (EMA) accelerated assessment program. After review, CHMP recommended that Empliciti® should be used in combination with lenalidomide and dexamethasone for multiple myeloma patients who have received at least one prior therapy. This EMA recommendation will be sent to the European Commission of the European Union, the body that will make the final decision on authorizing the marketing of Empliciti®’s use. To learn more, click HERE.

Boston Celtics Sink Baskets and Donations to the IMF
The International Myeloma Foundation is thrilled to announce that this NBA season, the organization’s research and education programs will be the winners in Takeda Oncology’s new campaign “3 Points for Patients.” Each time one of the 17-time champion Boston Celtics sinks a 3-point basket during the regular NBA season, Takeda Oncology will make a donation to the IMF. With the high-scoring Celtics’ track record, that could result in an additional $25,000 to support the IMF. Learn more from this video with Celtics’ Head Coach Brad Stevens.

Getting Serious -and Silly- About Healthy Eating
We humans are obsessed with and confused by food. In his blog this week, IMF Chairman Dr. Brian Durie considers two recently published books that illustrate both ends of the spectrum. “I'll Have What She's Having: My Adventures in Celebrity Dieting” is a wry look at the eating habits of the fit and famous (Gwyneth Paltrow, Elizabeth Taylor, Beyoncé). “Fat Chance” is a more serious examination of the real dangers of sugar and processed foods. To read Dr. Durie’s blog, click HERE.

FDA Approves New Kyprolis® (carfilzomib) combination therapy for the treatment of patients with RRMM.
Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy. Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval.

The Black Swan Research Initiative® Is the “Myeloma Moonshot”
Many of the approaches to curing cancer Vice President Joe Biden advocates as part of the much-discussed “cancer moonshot” have been part of the IMF’s Black Swan Research Initiative since its launch in 2012. In his blog this week, IMF Chairman Dr. Brian Durie says that collaboration and putting an end to research “silos” promise to bring us closer to a cure for myeloma. To read Dr. Durie’s blog, click HERE.

The International Myeloma Foundation (IMF) Appoints Dr. Rafat Abonour as New Medical Liaison to Support Organization’s European Program Expansion

Myeloma expert Dr. Rafat Abonour as IMF Medical Liaison. Dr. Abonour’s appointment follows the foundation’s recent appointment of French myeloma researcher Prof. Jean-Luc Harousseau, MD. Both men will help accelerate the IMF’s mission to affect positive change around the world.

Click here to view the replay of the Best of ASH 2015 Teleconference
Now that the American Society of Hematology’s (ASH) 2015 annual meeting has come to a close, attendees are sorting through the breadth of knowledge, research, and educational information shared. To simplify the latest trends in myeloma research, the IMF will present a free teleconference: “The Best of ASH 2015: What Patients & Caregivers Need to Know.” Dr. Brian Durie will host this ninety-minute session on Thursday, January 7, 2016, at 4 PM PT / 7 PM ET. If you tune into the teleconference, you will also have a chance to participate—30 minutes of this teleconference will feature a question and answer session with Dr. Durie. To pre-register for this event today, click HERE.

International Myeloma Foundation (IMF) Accelerates Global Expansion with Appointment of Prof. Jean-Luc Harousseau MD
The International Myeloma Foundation is pleased to announce that renowned myeloma researcher Prof. Jean-Luc Harousseau, MD will join the organization as Medical Education and Research Consultant to help accelerate the IMF’s global expansion and outreach efforts in Asia and Europe. With more than 30 years of experience in the field of hematology, Prof. Harousseau was a founding member and served as President of Intergroupe Français du Myélome (IFM), whose clinical trials have significantly contributed to improvements in the prognosis of multiple myeloma.

Three Holiday Presents for Myeloma Patients
With the recent FDA approvals of the myeloma drugs Darzalex (daratumamab), Ninlaro (ixazomib) and Empliciti (elotuzamab), the end of 2015 offered many holiday presents for myeloma patients. But, as IMF Chairman Dr. Brian Durie writes in his blog this week, in the New Year, myeloma doctors will need to figure out how to use these drugs in a clinical setting. To read Dr. Durie’s blog, click HERE.

previous     next      view all